These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34494564)

  • 1. Microbiome in sputum as a potential biomarker of chronicity in pulmonary resistant to rifampicin-tuberculosis and multidrug-resistant-tuberculosis patients.
    Wiqoyah N; Mertaniasih NM; Artama WT; Matsumoto S
    Int J Mycobacteriol; 2021; 10(3):260-267. PubMed ID: 34494564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The occurrence of multidrug-resistant Mycobacterium tuberculosis from patients of pulmonary tuberculosis.
    Iqbal A; Shafique M; Zahoor MA; Muzammil S; Nawaz Z; Jabbar A; Khurshid M; Hussain R; Islam MA; Almatroudi A; Allemailem KS; Rasool MH; Aslam B
    J Infect Dev Ctries; 2022 Apr; 16(4):698-704. PubMed ID: 35544633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].
    Tan S; Ding X; Tan Y; Cai X; Li Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):915-8. PubMed ID: 25609129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
    Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
    Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia.
    Silitonga P; Jiang W; Wyatt S; Burhan E; Kes EFM; Long Q
    Trop Med Int Health; 2023 Jan; 28(1):43-52. PubMed ID: 36477995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.
    Ahmed S; Shukla I; Fatima N; Varshney SK; Shameem M; Tayyaba U
    Int J Mycobacteriol; 2018; 7(4):315-327. PubMed ID: 30531028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of efficiency of nested multiplex allele-specific PCR assay for detection of multidrug resistant tuberculosis directly from sputum samples.
    Mistri SK; Sultana M; Kamal SM; Alam MM; Irin F; Nessa J; Ahsan CR; Yasmin M
    Lett Appl Microbiol; 2016 May; 62(5):411-8. PubMed ID: 26972777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study.
    Yu Q; Luo H; Hu S; Sun D; Nie Q; Yan J
    Front Cell Infect Microbiol; 2023; 13():1118424. PubMed ID: 37197206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
    Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
    BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.
    Muñoz-Torrico M; Caminero Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Ergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
    Rev Port Pneumol (2006); 2017; 23(1):27-30. PubMed ID: 28043788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
    PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
    Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
    PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
    Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
    BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.